Sinus Surgery Articles & Analysis
15 news found
(Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced positive results of an observational, cohort study using real-world evidence (RWE) data from adult patients with chronic rhinosinusitis (CRS) with or without nasal polyps who underwent endoscopic sinus surgery (ESS). ...
The trial will enroll approximately 180 CRS patients who have failed medical management and have not had a prior sinus surgery, randomized 2:1 to receive either LYR-210 (7500µg MF) or control. ...
Lyra's lead product candidate, LYR-210, is entering Phase 3 clinical development for the treatment of chronic rhinosinusitis (CRS) as an alternative to primary sinus surgery. Lyra's second product candidate, LYR-220, is entering Phase 2 development and is designed to be an alternative to revision CRS sinus surgery and ...
Intersect ENT’s PROPEL Contour is a drug-eluting, bioabsorbable sinus implant that is placed in the frontal sinus (between the eyebrows) following sinus surgery. ...
Zachary Soler, MD, MSc, Associate Professor of Otolaryngology at Medical University of South Carolina (MUSC) and practicing Otolaryngologist at the MUSC Sinus Center. Dr. Soler is a Global Coordinating Principal Investigator for Lyra's upcoming Phase 3 ENLIGHTEN program for LYR-210, and will provide an overview of the 6-month follow up data from the LANTERN Phase 2 study of ...
LYR-210 is designed as a non-invasive alternative to sinus surgery for the millions of CRS patients who have failed medical management. ...
“With 4 million patients failing medical management annually, chronic rhinosinusitis is described in the literature as an ‘unrecognized epidemic’ due to its high prevalence, substantial impact on patient quality of life, and significant limitations of treatment options.1 ENTs are eager for new options to help their CRS patients who have failed medical management but want to ...
The results demonstrate that XTreo™ MF provides targeted, sustained and efficient dosing to local sinus tissues that is superior to intranasal corticosteroid sprays (INCS). ...
Lyra’s lead product candidate, LYR-210, is entering Phase 3 clinical development for the treatment of chronic rhinosinusitis as an alternative to primary sinus surgery. Lyra’s second product candidate, LYR-220 which is entering Phase 2 development, is designed to be a potential preferred alternative to revision sinus ...
"After years of pioneering technology to help patients heal following sinus surgery, we welcome the integration of Intersect ENT's portfolio into Medtronic. ...
PROPEL Contour is specifically designed to maintain patency and reduce inflammation, and conform to the sinus ostia (openings) by focusing mechanical support and steroid delivery where it is needed to optimize sinus surgery outcomes. ...
The EXPAND study’s primary objective is to evaluate the efficacy of the Company’s PROPEL® Contour (mometasone furoate) sinus implant when placed in the frontal sinus ostium following in-office balloon dilation in patients with chronic rhinosinusitis (CRS) as compared to balloon sinus dilation alone. ...
CMS has now attached an ASP to J7402, “mometasone furoate sinus implant, (sinuva), 10 micrograms.” Previously, a single code covered both products despite their substantial differences. ...
(Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the U.S. availability of the new Straight Delivery System (“SDS”) packaged with the company’s PROPEL® Mini (mometasone furoate) Sinus Implant. The combined packaging of the SDS with PROPEL Mini received premarket ...
If you’ve ever had an awful sinus infection, you know how painful, and quite frankly, how much of a drag it is. But most of us don’t have Chronic Sinusitis, which consists of a sinus infection lasting longer than 3 months (despite treatment), according to the Mayo Clinic. ...